Humira Biosimilar Market, By Product Type, By Indication, By Distribution Channel, By Patient Age, By Geography

Description

Humira Biosimilar Market is estimated to be valued at USD 1,942.6 Mn in 2026 and is expected to reach USD 9,848.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 26.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,942.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	26.10%	2033 Value Projection:	USD 9,848.8 Mn

Humira is a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis and is the most popular biologic medication in the world. Following the expiration of patent protection for humira in some regions, biosimilars are highly similar copies of biologic medications in terms of safety, efficacy, and quality. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options. Biosimilars have been proven to be just as effective and safe as the original biologic medications, making them a viable alternative for patients with conditions like psoriasis and rheumatoid arthritis. Additionally, the availability of biosimilars promotes innovation in the pharmaceutical industry, as it encourages manufacturers to develop more affordable treatment options without compromising quality. This competition in the market can drive down prices and increase accessibility for patients, ultimately leading to improved healthcare outcomes. Furthermore, the introduction of biosimilars can also enhance patient choice and autonomy, allowing them to select the most suitable and cost-effective treatment for their specific needs.

Market Dynamics

Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment is major factors expected to drive growth of the global humira biosimilar market during the forecast period.

For instance, the market for multiple humira biosimilars has been approved and introduced in North America, which has led the way in the adoption of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.

However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper the growth of the global cerebral angiography market over the forecast period.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global humira biosimilar market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Rani Therapeutics Holdings, Inc., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Viatris Inc., and Alvotech.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market.

Market Segmentation

By Product Type (Revenue, USD Mn, 2021 - 2033)
Biosimilar Humira (Adalimumab)
Interchangeable Biosimilar Humira
By Indication (Revenue, USD Mn, 2021 - 2033)
Rheumatoid Arthritis
Psoriasis
Crohn's Disease
Ulcerative Colitis
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis
Other Autoimmune Conditions
By Patient Age (Revenue, USD Mn, 2021 - 2033)
Adult Patients
Pediatric Patients
Geriatric Patients
By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Top companies in Global Humira Biosimilar Market
Amgen
Samsung Bioepis Co., Ltd.
Sandoz International GmbH (Novartis AG)
Mylan N.V.
Boehringer Ingelheim International GmbH
Pfizer Inc.
Fresenius Kabi AG
Coherus BioSciences, Inc.
Biogen Inc.
AbbVie Inc.
Celltrion Inc.
Rani Therapeutics Holdings, Inc.
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Viatris Inc.
Alvotech

Product Code: CMI5925

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Patient Age
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Patent expiration
- Cost savings
- Increasing prevalence of autoimmune diseases
- Favorable regulatory environment
Market Restraints
Market Opportunity
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers Acquisitions, and Collaborations

4. Global Humira Biosimilar Market, By Product Type, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Biosimilar Humira (Adalimumab)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Interchangeable Biosimilar Humira
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

5. Global Humira Biosimilar Market, By Indication, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Juvenile Idiopathic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Other Autoimmune Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

6. Global Humira Biosimilar Market, By Patient Age, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

7. Global Humira Biosimilar Market, By Distribution Channel, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

8. Global Humira Biosimilar Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/ Region, 2021 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Samsung Bioepis Co.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sandoz International GmbH (Novartis AG)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Mylan N.V.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Boehringer Ingelheim International GmbH
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Fresenius Kabi AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Coherus BioSciences
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Biogen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Celltrion Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Rani Therapeutics Holdings, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Viatris Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Alvotech
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Analysts' Views

10. Section

References
Research Methodology
About us